Progranulin and insulin-like Growth Factor Binding Protein-2 as Biomarkers of Disease Activity and Pathological Changes in Lupus Nephritis

2017 ◽  
Vol 44 (02) ◽  
pp. 121-127
Author(s):  
Samar Goma ◽  
Marwa Abdelaziz ◽  
Eman El-Hakeim ◽  
Mona El Zohri ◽  
Sohair Sayed
Keyword(s):  
Growth Factor ◽  
Kidney Disease ◽  
Lupus Nephritis ◽  
Disease Activity ◽  
Renal Biopsy ◽  
Activity Index ◽  
Binding Protein ◽  
Disease Activity Index ◽  
Insulin Like Growth Factor ◽  
Factor Binding

Abstract Background Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease, characterised by the production of auto-antibodies and the formation of immune complexes due to the polyclonal activation of T and B lymphocytes, which results in tissue and organ damage. During inflammation, neutrophils and macrophages release serine proteases to cleave progranulin (PGRN) into granulin, which exerts its pro-inflammatory effects that counteract the anti-inflammatory effects of intact PGRN. It is suggested that insulin-like growth factor binding protein-2 (IGFBP-2) is a dependable biomarker of renal deterioration but it is still unclear if it has high sensitivity and specificity for discriminating SLE-caused kidney disease from other-cause kidney disease.This study aimed to investigate the diagnostic value of PGRN and ILGFBP-2 in patients with lupus nephritis (LN) and the correlation of these biomarkers with disease activity and renal biopsy pathology. Patients and methods Patients with SLE (n=25) and chronic kidney disease (CKD) (n=25), and age- and sex-matched controls (n=25) were enrolled in the study. Serum PGRN and ILGFBP-2 levels were measured for each group. Results Disease duration was 4.78±4.26 years in the SLE patients. The mean SLE Disease Activity Index score was 15.04±7.54. All renal biopsy results were class 2, 3, and 5 with a percentage of 32, 24, and 44% respectively. PGRN and ILGFBP-2 were significantly higher in SLE patients (p<0.001 all) than in the CKD and control groups. All patients with high levels of biomarkers showed higher values of SLE disease activity. No significant difference was noted between active and inactive LN or classes of renal biopsy with PGRN and ILGFBP-2. Conclusion PGRN and ILGFBP-2 are significantly elevated in SLE compared to CKD and the general population and were associated with the SLE Disease Activity Index but not with active LN or classes of renal biopsy.

scholarly journals Insulin-Like Growth Factor Binding Protein-2 in Systemic Lupus Erythematosus Patients as a Marker of Lupus Nephritis Disease

2021 ◽  
pp. 1-13
Author(s):  
Zeinab N. ELRefeai ELgody ◽  
Ghadah Mahmoud Alghzaly ◽  
Mohammed Attia Saad Attia ◽  
Mohammed Mohammed Albedawey
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Growth Factor ◽  
Lupus Nephritis ◽  
Lupus Erythematosus ◽  
Activity Index ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
Systemic Lupus ◽  
Factor Binding ◽  
Significant Difference

Background: One of the members of Insulin-like Growth Factor Binding Protein family is IGFBP-2 that binds to the Insulin-like Growth Factor (IGF) receptors to regulate IGF biological activities. In nephrotic syndrome IGFBP-2 has also been reported to be increased in children and IGFBP-2 considers as predictor for longitudinal deterioration of kidney function in Type 2 Diabetes. The aim of the work was to assess insulin like growth factor binding protein-2 as a marker for activity of lupus nephritis. Methods: A cross-sectional study was carried out on 80 subjects and was divided on: Group1: 60 patients with Systemic lupus erythematosus which were subdivided into: (a) 40 Systemic lupus patients with nephritis. (b) 20 Systemic lupus patients without nephritis. Group 2: 20 healthy persons as control (Healthy controls). Results: there were statistically significant difference in ILGRFBPs2 P1, P2 while P3 was insignificant, Regarding the Systemic Lupus Erythematosus Disease Activity Index (SLEDI) score, there was significant difference between group IA and IB while statistically significant positive correlation between ILGFBPs2 and renal SLEDI score. Regarding ILGFBPs2, Anti-ds DNA Ab titer, renal biopsy classes and activity index, there was a statistically significant positive correlation. Regarding chronicity index and renal SLEDI score, there was insignificant correlation. Conclusion: Serum IGFBP‐2 is a promising biomarker for lupus nephritis, reflecting disease activity and chronicity changes in renal pathology.

scholarly journals Insulin-Like Growth Factor Binding Protein-4 as a Marker of Chronic Lupus Nephritis

PLoS ONE ◽  
2016 ◽  
Vol 11 (3) ◽  
pp. e0151491 ◽  
Author(s):  
Tianfu Wu ◽  
Chun Xie ◽  
Jie Han ◽  
Yujin Ye ◽  
Sandeep Singh ◽  
...  
Keyword(s):  
Growth Factor ◽  
Lupus Nephritis ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
Factor Binding

scholarly journals Association between serum insulin like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein-3 levels and chronic kidney disease in diabetic patients

2020 ◽  
Vol 10 (1) ◽  
pp. e05-e05
Author(s):  
Volha N. Vasilkova ◽  
Tatsiana V. Mokhort ◽  
Ivan Y. Pchelin ◽  
Valentina K. Bayrasheva ◽  
Elena P. Naumenko ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Growth Factor ◽  
Kidney Disease ◽  
Cystatin C ◽  
Binding Protein ◽  
Diabetic Patients ◽  
Insulin Like Growth Factor ◽  
Factor Binding ◽  
Patients With Diabetes ◽  
Igfbp 3

Introduction: Insulin-like growth factor-1 (IGF-1) is a potent mitogen for glomerular mesangial cells which can stimulate cell migration and the production of fibronectin, proteoglycan, and type IV collagen, thereby promoting the development of the chronic kidney disease (CKD) in patients with diabetes. Objectives: The aim of the study was to assess the associations between serum levels of IGF-1 and insulin-like growth factor-binding protein-3 (IGFBP-3) and CKD in diabetic patients. Patients and Methods: We investigated 102 Belarusian men and women with diabetes type 2 aged 56.67±0.81 years. Control group included 68 healthy people the same age. We estimated GFR with the use of the CKD-EPI creatinine-cystatin C equation to determine eGFRcr_cys. Serum total IGF-1 and IGFBP-3 levels were measured using immunoradiometric assay (IRMA) (Beckman Coulter, Czech Republic s.r.o.). Results: Patients with diabetes had significantly lower level of IGF-1 than controls. However, IGFBP-3 levels were similar in the two groups. Diabetic patients with CKD had significantly higher levels of IGF-1 and IGFBP-3 than diabetic patients without CKD (P=0.0031). However, according to multivariate analysis, only IGF-1 and cystatin C were associated with renal impairment. In detail, the odds of having eGFR<60 mL/min/1.73 m2 increased with rising IGF-1 levels (OR: 1.025, [CI 1.002-1.048]). Conclusion: Our study revealed that higher serum IGF-1 levels were positively associated with CKD in patients with diabetes. We suggest that IGF-1 might be a predictor of CKD in patients with diabetes. Further research is necessary to confirm the observed this association and to detect the causal relations.

scholarly journals AB0441 ASSOCIATION OF CO-POSITIVITY FOR ANTI-DSDNA, -NUCLEOSOME, AND -HISTONE ANTIBODIES AND DISEASE ACTIVITY IN PATIENTS WITH LUPUS NEPHRITIS: RESULTS FROM THE KORNET REGISTRY

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1519.2-1519
Author(s):  
D. J. Park ◽  
S. E. Choi ◽  
H. Xu ◽  
J. H. Kang ◽  
S. S. Lee
Keyword(s):  
Lupus Nephritis ◽  
Disease Activity ◽  
Renal Biopsy ◽  
Lupus Erythematosus ◽  
Kidney Biopsy ◽  
Activity Index ◽  
Disease Activity Index ◽  
Induction Treatment ◽  
Rapid Decline

Background:Recent studies have shown that the simultaneous positivity of anti-double stranded DNA, -nucleosome, and -histone antibodies (3-pos) is prevalent in lupus nephritis (LN) patients compared to non-renal systemic lupus erythematosus (SLE) patients.Objectives:The aim of this study was to define the clinical, biologic, histopathologic, and prognostic differences according to the simultaneous reactivity to those antibodies in Korean patients with biopsy-proven LN.Methods:We studied 102 patients who underwent kidney biopsy prior to the start of induction treatment and who were subsequently treated with immunosuppressives and followed-up for more than 12 months. Sociodemographic, clinical, laboratory, and treatment-related data at the time of kidney biopsy and during follow-up were obtained by a review of patients’ charts. Antibodies were detected by immunoblot analysis or ELISA at the time of renal biopsy.Results:Fifty-eight (35.4%) of the total of 102 LN patients had 3-pos. In comparison with non-3-pos patients, the patients with 3-pos showed a higher SLE Disease Activity Index-2000 score (P=0.002), lower lymphocyte level (p=0.004), higher proportion of proteinuria >3.5 g/24 hr (p=0.005), and higher positivity of urinary sediments (p=0.005) at the time of renal biopsy. In the renal histopathologic findings, the patients with 3-pos had more proliferative LN (p=0.015) and also showed more endocapillary hypercellularity, sub-endothelial hyaline deposits, fibrinoid necrosis/karyorrhexis, and cellular crescents in the disease activity index (p=0.016, p=0.045, p=0.002, and p=0.022, respectively), as well as a higher activity score (p=0.011). After a median follow-up of 83.2 months, rapid glomerular filtration rate decline was frequently observed in patients with 3-pos compared to those without (p=0.012).Conclusion:Our findings suggest that 3-pos is related to severe LN and, furthermore, that patients with 3-pos show a rapid decline of renal function compared to those without.Disclosure of Interests:None declared

Regulation of insulin-like growth factor-binding protein-1 in rat serum

Diabetes ◽  
1994 ◽  
Vol 43 (2) ◽  
pp. 232-239 ◽  
Author(s):  
M. S. Lewitt ◽  
H. Saunders ◽  
J. L. Phyual ◽  
R. C. Baxter
Keyword(s):  
Growth Factor ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
Rat Serum ◽  
Factor Binding
Sign in / Sign up

Export Citation Format

Share Document